Shares of SummitTherapeutics (NASDAQ: SMMT) rocketed as high as 75.2% Monday, before settling into a 57.5% gain as of 1:27 PM EDT. Aa an early-stage biotech, a potential blockbuster drug would be ...
Shares of SummitTherapeutics (NASDAQ: SMMT) recently jumped in response to positive clinical trial results for its experimental cancer therapy. Results of the phase 3 Harmoni-2 trial suggest ...
Instead of delivering two therapies, ivonescimab from SummitTherapeutics, IMM2510 from Instil Bio, and BNT327 from BioNTech are all bispecific antibodies that inhibit VEGF and the PD-1 checkpoint ...
Shares of SummitTherapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage trial data showing that its experimental lung-cancer treatment topped ...